Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 2/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17148999 | 0.78 | NOTUM (0.48) | BACE1BACE2 | |
| SCHEMBL2659000 | 0.77 | KDM4E (0.35) | BRD4LPLLIPGHCRTR1HCRTR2 | |
| SCHEMBL31401292 | 0.76 | LPL (0.37) | BACE1BACE2LPLLIPGJAK2 | |
| SCHEMBL2659535 | 0.76 | LPL (0.37) | BACE1BACE2LPLLIPGJAK2 | |
| SCHEMBL24630498 | 0.75 | LPL (0.46) | LPLLIPGJAK2BTK | |
| SCHEMBL31057611 | 0.75 | PIN1 (0.33) | BRD4PIN1LPLLIPGHPGDS | |
| SCHEMBL20968600 | 0.74 | LIPG (0.49) | LPLLIPGJAK2BTK | |
| SCHEMBL2659046 | 0.73 | CYP17A1 (0.40) | BACE1LPLLIPG | |
| SCHEMBL18059705 | 0.73 | FEN1 (0.43) | LPLLIPG | |
| SCHEMBL12804460 | 0.73 | CTSA (0.41) | BRD4PIN1HCRTR1HCRTR2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11053241-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200172540-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
| WO-2020112937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | BRD4 223/4885BACE1 4408/4885BACE2 3542/4885 |
| US-11053241-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | BRD4 223/4885BACE1 4408/4885BACE2 3542/4885 |
| US-20200172540-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | BRD4 223/4885BACE1 4408/4885BACE2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.